## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

McPh	nerson's Limited	
ABN 98 00	4 068 419	
We (th	he entity) give ASX the following i	nformation.
	1 - All issues ust complete the relevant sections (attach sl	neets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Unlisted Performance Rights.
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	783,000 Performance Rights lapsed.
3	Principal terms of the <sup>+</sup> securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion)	Performance rights lapsed in accordance with their terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A
5	Issue price or consideration	N/A
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	N/A
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the subject of this Appendix 3B, and comply with section 6i	No.
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	<sup>+</sup> Issue dates	Lapse Date: 18 September 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	104,771,194	Ordinary Shares
		Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	2,330,000	Unlisted Performance Rights

Part 2 - Pro rata issue				
11	Is security holder approval required?	N/A		
12	Is the issue renounceable or non-renounceable?	N/A		
13	Ratio in which the *securities will be offered	N/A		
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A		
15	<sup>+</sup> Record date to determine entitlements	N/A		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A		
17	Policy for deciding entitlements in relation to fractions	N/A		
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	N/A		
	Cross reference: rule 7.7.			
19	Closing date for receipt of acceptances or renunciations	N/A		
20	Names of any underwriters	N/A		
21	Amount of any underwriting fee or commission	N/A		
22	Names of any brokers to the issue	N/A		
23	Fee or commission payable to the broker to the issue	N/A		

N/A

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

10

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of \*securities (tick one)
- (a) \*Securities described in Part 1(a)

(b)		All other *securities	
			f the escrowed period, partly paid securities that become fully paid, employee dds, securities issued on expiry or conversion of convertible securities
Entiti	es tha	t have ticked box 34(a)	
Addit	ional s	ecurities forming a new clas	s of securities
Tick to docume		e you are providing the information	on or
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36		If the *securities are *equity *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional or of holders in the categories
37		A copy of any trust deed for the	e additional <sup>+</sup> securities
Entiti	es tha	t have ticked box 34(b)	
38		per of *securities for which ation is sought	N/A
39	+Class	s of <sup>+</sup> securities for which	N/A
57		tion is sought	14/14
40	respected existing.  If the rank e  the the pa (in dis	rticipate for the next dividend, n the case of a trust, stribution) or interest payment	N/A
	rai rel	e extent to which they do not nk equally, other than in lation to the next dividend, stribution or interest payment	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at the 
  time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Cian hana	Wound	Doto	19 <sup>th</sup> September, 2018
Sign here:	( <del>Director</del> /Company secretary)	Date:	
	Philip Bennett		
Print name:			

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figures capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	N/A		
<ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>			
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval			
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period			
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items  Subtract the number of fully paid fordinary.			
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period			
"A"			

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15		
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
<ul> <li>Under an exception in rule 7.2</li> </ul>		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount 7.1A that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"		
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.